an affiliate of
We Need Your help as a 50-State Network Advocate!
Now is your time to be heard
Join the 50-State Network here
The 50-State Network is a grassroots advocacy organization comprised of patients like you. We are working to share the patient perspective, which is crucial in the State and Federal health policy and regulatory arenas. Patients need a voice in all conversations that relate to our access to treatment, safety, or the quality of our care. This community is made up of patients living with diverse chronic illnesses, including rheumatoid arthritis, lupus, and psoriasis, and the people who care about them. The 50-State Network is about transforming pain into purpose, empowering those that may feel victimized by disease. Our focus is on repurposing the energy of frustration, despair, and helplessness into positive mobilization, action, and fair representation to benefit all of us. Our formula, which we offer to our fellow patients and their loved ones, is to take lemons and make lemonade...
Advocates in the news
GHLF-50 State banner
Fail First/ Step Therapy Advocacy Update

We want to share a quick update and applaud one of our 50-State Network advocates Danielle Yevsa who spoke up about Fail First/ Step Therapy practices in the New York Daily News.

8/3/16 – New York Step Therapy Campaign Rally

Patients, advocates and health care providers came together on the steps of the state capitol in Albany, NY, August 3rd, to call on Governor Andrew Cuomo to sign into law legislation aimed at ensuring that patients and their doctors have the final say in their medication treatment plans. During this past legislative session, both the […]

GHLF/50-SN activity at FDA Arthritis Advisory Committee Meeting July 12th & July 13th

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]